Few herbal preparations are as widely used and debated as echinacea, which, marketed as a natural remedy for colds, is often considered an alternative to conventional treatments. However, reports Medscape, experts say evidence supporting these claims remains uncertain, and it shows limited evidence of effectiveness.
The term echinacea suggests a single, well-defined preparation. But the name refers to several species, particularly Echinacea purpurea, E angustifolia, and E pallida, each with a distinct chemical composition.
Preparations also differ according to the parts of the plant used, including the root, aerial parts, or both. Extraction methods further alter the chemical profile, leading to substantial variation between the products.
Product variability
Preparations also differ across markets, making it difficult to compare studies, and while many studies have been conducted in the United States, a number of the products evaluated are often unavailable in other markets.
Echinacea contains a complex mixture of bioactive compounds, primarily alkamides, polysaccharides and caffeic acid derivatives, including chicoric acid, caftaric acid and echinacoside. Preclinical studies have shown immunomodulatory, anti-inflammatory and partial antiviral effects.
These findings appear pharmacologically promising, but a fundamental limitation remains: no single compound has been shown to reliably predict its clinical efficacy.
Because multiple bioactive compounds are being studied simultaneously, it remains unclear which component is the most important or whether any potential effect results from the combined action of several ingredients. Bioavailability also differs considerably between individual molecules.
As a result, preparations that appear similar on the label may still produce different pharmacologic effects in the body.
Clinical evidence
These challenges make it difficult to evaluate echinacea in rigorous clinical studies. A widely cited Cochrane review found no convincing overall benefit for treating colds with echinacea.
Although some individual studies have reported small effects, the authors did not support a broad clinical recommendation.
Review articles have suggested that echinacea may slightly reduce the frequency and severity of recurrent uncomplicated respiratory infections. Evidence was considerably weaker when echinacea was started after onset of symptoms rather than prophylactically.
A randomised control trial found no clinically meaningful effect when echinacea was used after the onset of symptoms.
Differences in plant species, plant parts and extraction methods further complicate the interpretation of the evidence. Because of this variability, current data do not support recommendations for specific preparations.
Echinacea is often marketed as a product that strengthens the immune system, leading to claims that are not supported by clinical evidence. Current evidence does not support routine therapeutic use for SARS-CoV-2 or other infectious diseases.
Even under favourable conditions, echinacea cannot replace vaccination, substitute for indicated anti-infective treatment, or eliminate the need for careful evaluation of complicated disease courses. However, it may be considered an optional complementary approach in mild upper respiratory infections.
Safe but not risk-free
The safety profile of short-term consumption of echinacea appears generally favourable. In controlled studies, adverse events occur at rates similar to those of placebo, suggesting that echinacea is usually well tolerated in otherwise healthy adults receiving standard doses. This favourable safety profile probably contributes to its widespread use.
Typical side effects include gastrointestinal discomfort, occasional skin reactions, and rare allergic reactions. Caution is advised in individuals with atopy or known sensitivity to plants in the Asteraceae family.
Although the evidence proved few clearly documented serious drug interactions, some evidence suggests that consumption of echinacea may affect cytochrome P450 enzymes.
Potential effects on CYP1A2 and other metabolising enzymes have been reported. This does not necessarily make echinacea unsafe; however, caution is warranted in individuals receiving complex medication regimens.
Limited benefit
Echinacea is neither ineffective nor a miracle treatment. This plant has pharmacologically active compounds and may provide a modest preventive benefit against uncomplicated upper respiratory infections.
However, any potential benefits appear to be limited and depend heavily on the specific preparation and extract used. The current evidence is not strong enough to support comprehensive clinical recommendations.
Echinacea is best considered an optional complementary measure rather than a primary treatment for respiratory infections.
Medscape article – Questions Persist Over Echinacea for Preventing Colds (Open access)
See more from MedicalBrief archives: